Q1 Earnings Forecast for Immunic Issued By William Blair

Key Points

• William Blair predicts Immunic will report a Q1 2026 earnings per share of ($0.16), while the consensus estimate for the full year is ($0.94) per share.
• Immunic's recent quarterly earnings report showed a loss of ($0.20) EPS, missing analysts' estimates by ($0.02).
• Immunic currently has a Buy consensus rating, with price targets ranging from $5.00 to $10.00 among various analysts.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Immunic in a note issued to investors on Thursday, August 7th. William Blair analyst M. Minter anticipates that the company will earn ($0.16) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic's Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.17) EPS.

A number of other equities research analysts have also issued reports on IMUX. D. Boral Capital restated a "buy" rating and issued a $10.00 price target on shares of Immunic in a research report on Friday. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Immunic in a research note on Thursday, May 1st. Finally, B. Riley restated a "buy" rating and issued a $5.00 target price (down from $6.00) on shares of Immunic in a report on Friday, May 23rd. One research analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Immunic currently has an average rating of "Buy" and a consensus price target of $7.50.

Immunic Price Performance

NASDAQ IMUX traded up $0.00 during trading hours on Monday, hitting $0.85. 1,302,725 shares of the company's stock traded hands, compared to its average volume of 1,148,710. The company has a market capitalization of $84.07 million, a PE ratio of -0.69 and a beta of 1.39. Immunic has a 52-week low of $0.56 and a 52-week high of $2.11. The firm's 50-day moving average is $0.85 and its 200-day moving average is $0.97.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02).

Institutional Trading of Immunic

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC lifted its position in Immunic by 480.6% in the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company's stock valued at $580,000 after buying an additional 479,846 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Immunic by 45.6% during the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock valued at $567,000 after acquiring an additional 177,542 shares during the last quarter. Barclays PLC purchased a new stake in shares of Immunic in the 4th quarter valued at approximately $84,000. Invesco Ltd. acquired a new position in shares of Immunic in the 4th quarter worth approximately $37,000. Finally, Focus Partners Wealth lifted its holdings in shares of Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock worth $2,168,000 after acquiring an additional 23,610 shares during the last quarter. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.